Direct bilirubin < 3.0 mg/dL
Direct bilirubin =< 2.0 mg/dL
Bilirubin < 1.4 mg/dl
Bilirubin =< 1.5 mg/dL
Bilirubin < 1.5 mg/dl
Bilirubin > 2.0 mg/dL
Direct bilirubin ? 1.5 mg/dL or total bilirubin ? 1.5 mg/dL
Direct bilirubin ? 3.0 mg/dL (50 mmol/L)
Bilirubin =< 1.5 mg/dL
Direct bilirubin < 2.0 mg/dL
Bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)
Bilirubin < 2.0 mg/dL
Bilirubin ? 2.0 mg/ml
Bilirubin > 1.15 mg/dL
Direct bilirubin > 2.0 mg/dL
Bilirubin < 1.5 mg/dL
Bilirubin =< 3.0 mg/dL (obtained within three days prior to study treatment)
Patients have normal organ function: Hemoglobin ? 8.5 gm/dL, Platelets ? 50,000 /µL, Creatinine ? 2 mg/dL, AST and ALT < 10 X upper normal limit of the current institution; bilirubin < 3.0 mg/dL
Direct or conjugated bilirubin < 3 mg/dl
Patients with bilirubin levels > 2 mg/dL
Bilirubin =< 1.5 mg/dl
Bilirubin =< 2 mg/dL
Obtained within 14 days prior to enrollment: bilirubin =< 1.5 mg/dL
Direct bilirubin =< 2.0 mg/100 ml
Adequate hematological, hepatic, and renal parameters; i.e., hemoglobin > 10 g/dL, creatinine < 3.5 mg/dL, bilirubin < 1.5 mg/dL , and aspartate aminotransferase, alanine aminotransferase < 50 U/L, and alkaline phosphatase < 130 U/L.
Direct bilirubin =< 2.0 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin =< 2.0 mg/dl
Bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)
Bilirubin > 3.0 mg/dL
Bilirubin less than or equal to 2.0 mg/dl
Direct bilirubin =< 2.0 mg/dl
Bilirubin =< 2.0 mg/dL
Bilirubin less than or equal to 3.0 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin >= 1.5 mg/dL
Bilirubin less than or equal to 2 mg/dL
Bilirubin =< 1.5 mg/dL
Direct bilirubin < 1 mg/dl
To commence second line irinotecan, bilirubin should be < 1 mg/dL; if between 1-2 mg/dL initial dose should be reduced by one dose level; if > 2 mg/dL, then irinotecan will not be used
Bilirubin < 1.5 mg/dL
Bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)
Within 2 weeks of enrollment: Bilirubin =< 2.0 mg/dl
Bilirubin =< 2.5 mg/dL
Bilirubin =< 2 mg/dL
Bilirubin =< 1.5 mg/dL
Direct bilirubin =< 2.0 mg/dl
Bilirubin =< 1.5 mg/dL
Bilirubin > 3.0 mg/dL
Bilirubin =< 2.0 mg/dl
Bilirubin =< 3.0 mg/dL
Direct bilirubin of =< 2 mg/dL
Bilirubin level at/above 100 umol per liter (5.8 mg/dL)
Bilirubin < 2 mg/dL
Bilirubin =< 1.5 mg/dL (=< 3.0 mg/dL with liver metastasis)\r\n* Subjects with Gilbert's disease may have bilirubin up to 2.5 mg/dL (or 3.0 mg/dL with liver metastasis)
Bilirubin =< 2 mg/dL
Bilirubin =< 1.5 x upper limit of normal unless the patient is receiving protease inhibitor therapy (e.g. indinavir, ritonavir, nelfinavir, or atazanavir) known to be associated with increased bilirubin, in which case total bilirubin =< 7.5 mg/dL with direct fraction =< 0.7 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin < 1.5 mg/dl
Bilirubin =< 1.95 mg/dL
Even if organ function abnormalities are considered due to tumor, the upper limit for bilirubin is =< 2.6 mg/dL and creatinine =< 3 mg/dL
Patients must have bilirubin =< 1.5 mg/dl
Bilirubin =< 2.5 mg/dL
Bilirubin < 1.5 mg/dL
Direct bilirubin >= 3.1 mg/dl
Bilirubin =< 2.0 mg/100 ml
Bilirubin < 2.0 mg/dl, or total bilirubin =< 4.5 mg/dl with direct fraction =< 0.3 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy
Bilirubin < 1.5 mg/dl
Adequate renal and hepatic function (creatinine ? 2.0 mg/dl, bilirubin ? 2.0 mg/dl, AST and ALT ? 4X upper limit of normal range).
Bilirubin < 2mg/dL
Bilirubin =< 2.0 mg/dL
Direct bilirubin < 1.4 mg/dL (23.9 micromoles/L); Note: a total bilirubin of < 1.4 mg/dL (23.9 micromoles/L) is acceptable to meet this requirement
Bilirubin =< grade 1\r\n* If bilirubin is 2-3 mg/dL, but direct bilirubin is normal then patient will be considered eligible
Total bilirubin =< 1.5 mg/dL or direct bilirubin =< 0.4 mg/dL
Direct bilirubin < 1.4 mg/dL (23.9 micromoles/L); note: a total bilirubin of < 1.4 mg/dL (23.9 micromoles/L) is acceptable to meet this requirement
Bilirubin =< 2.0 mg/dL
Bilirubin =< 2.0 mg/dl
Bilirubin =< 2.0 mg/dL within 2 weeks before baseline
Bilirubin =< 1.5 mg/dl
Total bilirubin < 4.5 mg/dl with direct fraction =< 0.3 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy
Pretreatment serum bilirubin =< 2.5 x ULN or total bilirubin < 4.5 mg/dl with direct fraction =< 0.3 mg/dl in patients for whom these abnormalities are felt to be due to protease inhibitor therapy
Direct bilirubin =< 2mg/dL
Bilirubin =< 2 mg/dl, within 14 days prior to registration
Direct bilirubin =< 1 mg/dL
Direct bilirubin > 1.5 mg/dL
Bilirubin < 1.5 mg/dL
Bilirubin =< 1.5 mg/dl
Bilirubin =< 2.0 mg/dL
Bilirubin < 2.0 mg/dL
Bilirubin < 2.0 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin =< 1.5 mg/dL within four weeks prior to randomization
Bilirubin < 2.0 mg/dL;
Bilirubin ? 1.5 mg/dl
Bilirubin ? 1.5 mg/dl
Bilirubin < 2.0 mg/dL.
Bilirubin ? 2.5 mg/dL
Bilirubin < 1.5 mg/dL
Bilirubin less than or equal to 3.0 mg/dL
Bilirubin =< 3.0 mg/dl, unless considered due to tumor
Bilirubin < 2.0 mg/dl
Advanced bilirubin levels > 3 mg/dl
Bilirubin less than or equal to 2.0 mg/dl
Bilirubin =< 1.5 mg/dL
Bilirubin =< 2 mg/dL, unless due to chronic GVHD
Direct bilirubin < 2.0 mg/dl
Bilirubin =< 1.5 mg/dl
Bilirubin =< 3.0 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin < 2.0 mg/dL
Bilirubin =< 1.8 mg/dL within 4 weeks of enrollment
Within 30 days prior to initiation of protocol treatment: Bilirubin =< 1.5 mg/dL\r\n* Subjects with documented Gilbert’s disease may have bilirubin up to 2.5 mg/dL
Bilirubin =< 1.5 mg/dl
Bilirubin =< 2 mg/dl within 30 days prior to registration
Bilirubin < 2.0 mg/100 ml
Total bilirubin =< 3.0 mg/dL (or direct bilirubin < 1 mg/dL)
Direct bilirubin less than or equal to 3.0 mg/dL
Bilirubin =< 2.0 mg/dL
Bilirubin of < 3 mg/dl
Bilirubin < 3.0 mg/dl
Bilirubin =< 1.5 mg/dL
Bilirubin =< 2.0 mg/100 ml
Bilirubin =< 2.0 mg/dL
Elevation of bilirubin to > 3 mg/dl
Bilirubin < 2.0 mg/dL
Bilirubin less than or equal to 3.0 mg/dL (unless considered tumor related)
Bilirubin =< 2.0 mg/dL
Bilirubin =< 2.0 mg/dL
Bilirubin =< 2.0 mg/dL
Bilirubin =< 2 mg/dL
Bilirubin =< 2.0 mg/dL
PRIOR TO POST-TRANSPLANT IMMUNOTHERAPY: Bilirubin =< 2.0 mg/dL
Bilirubin < 2.0 mg/100 ml
Bilirubin =< 1.5 X upper limit of normal (ULN) unless the patient is receiving protease inhibitor therapy (i.e. indinavir, ritonavir, nelfinavir, and atazanavir) known to be associated with increased bilirubin: in this case total bilirubin =< 7.5 mg/dl and the direct fraction is =< 0.7 mg/dl
Direct bilirubin > 0.5mg/dL
Bilirubin < 1.5 mg/dl
Adequate liver function (bilirubin less than or equal to 3.0 mg/dl, unless considered due to tumor), and renal function (creatinine less than or equal to 3.0 mg/dl, unless considered due to tumor)
Bilirubin levels greater than 3 mg/dl
Direct bilirubin =< 1.4 mg/dL (if total bilirubin > 1.4 mg/dL)
Bilirubin =< 1.5 mg/dl
Bilirubin < 3 mg/dl unless due to disease
Bilirubin > 3.0 mg/dl
Bilirubin less than or equal to 1.5 mg/dL; even if organ function abnormalities are considered due to tumor, the upper limit for bilirubin is less than or equal to 2.0 mg/dL (unless due to hemolysis or Gilbert’s disease, i.e. mainly indirect bilirubin)
Bilirubin less than or equal to 3 mg/dL within 24 hours of enrollment
Bilirubin < 1.5 mg/dl
Bilirubin <1.5 mg/dL or direct bilirubin <1.0 mg/dL
Bilirubin =< 1.5 mg/dL
Direct bilirubin less than or equal to 3.0 mg/dL
Direct bilirubin equal to or less than 2.0 mg/dL
Bilirubin ?1.5 mg/dL
Bilirubin =< 1.6 mg/dL
Bilirubin =< 1.5 mg/dL
Bilirubin =< 1.50 mg/dL
Bilirubin > 2.0 mg/dL (26 umol/L)
Bilirubin > 1.6 mg/dL
Patients with bilirubin between 1.5-3.0 mg/dL due to lymphoma may be entered and doses adjusted
Bilirubin =< 2.0 mg/dL
Bilirubin level >= 3.7 mg/dL.
Bilirubin =< 1.5 mg/dl
Bilirubin > 1.4 mg/dl
Bilirubin < 2.0 mg/dL
Bilirubin < 2.0 mg/ dL
Bilirubin > 1.6 mg/dL
Bilirubin > 1.5 mg/dL